Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley

Episode 331

0:00-50:08

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Publisher

Business Of Biotech

Published

November 9, 2026

Duration

50 min

Format

Podcast

Category

Issues · Business

Source

RSS feed

Host

Ben Comer

BO

Business Of Biotech

@businessofbiotech

#managingrisk #growingneuroscienceportfolio #abbviesseankelley #management #lifesciences

The Nile